Groundwork Collaborative, a progressive think tank, has circulated an internal oversight blueprint naming Coinbase CEO Brian Armstrong and World Liberty Financial as potential targets for Democratic investigations. The 181-182 page document, circulated in early November 2026, focuses on individuals and corporations with ties to Donald Trump and examines how those relationships may have influenced policy or produced favorable treatment.
Armstrong is specifically flagged as a target for potential hearings, placing the head of the largest publicly listed U.S. crypto exchange alongside major companies including Tesla, Apple, and Amazon in the oversight conversation.
World Liberty Financial represents a more direct inclusion. The firm was co-founded by Trump's family members, who hold approximately 38% ownership. The blueprint was prepared by economic policy experts with input from Bharat Ramamurti and has been reviewed by figures connected to the Biden administration before circulating among Democratic lawmakers.
Recent Developments Prompt Timing
Coinbase received full U.S. trust charter approval from the Office of the Comptroller of the Currency on November 9, 2026. World Liberty Financial launched a token buyback program on November 5-6, 2026, reportedly funded by stablecoin reserves.
The blueprint treats both entities as part of a broader pattern of businesses that may have benefited from proximity to Trump, grouped alongside major corporations under shared themes of potential favoritism.
Implications for the Sector
For Coinbase, the trust charter approval—a business milestone expanding its operational capabilities—could become a subject of regulatory inquiry. For World Liberty Financial, the exposure is more immediate, given that a project co-founded and partly owned by Trump's family is a focal point for investigating Trump-linked favoritism.
Democratic lawmakers' adoption of the blueprint's priorities ahead of midterm elections could shape regulatory developments. The research notes that investors may react to adverse findings or major regulatory shifts, potentially causing market volatility.
